Two drug makers are edging toward being the first to reach the market with a treatment for lupus nephritis (LN), the acute inflammation of the kidneys caused by chronic systemic lupus erythematosus (SLE). There are currently no drugs approved by the US Food and Drug Administration for LN and only one approved for the chronic autoimmune condition.
Aurinia Pharmaceuticals Inc. announced on 26 May that it completed a rolling new drug application (NDA) submission to the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)